Impairment of enzymes called topoisomerases during brain growth might trigger the development of autism spectrum disorder, according to a study published in the journal Nature. When researchers inhibited these enzymes with a generic cancer drug, approximately 50 genes linked to the developmental disorder were silenced.

Full Story:

Related Summaries